CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 95 filers reported holding CYTOSORBENTS CORP in Q4 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $11,000 | -26.7% | 3,468 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $15,000 | -46.4% | 3,468 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $28,000 | +7.7% | 3,468 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $26,000 | -13.3% | 3,468 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $30,000 | +42.9% | 3,468 | +30.0% | 0.00% | 0.0% |
| Q4 2020 | $21,000 | 0.0% | 2,668 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $21,000 | -19.2% | 2,668 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $26,000 | +23.8% | 2,668 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $21,000 | +110.0% | 2,668 | 0.0% | 0.00% | – |
| Q4 2019 | $10,000 | -23.1% | 2,668 | 0.0% | 0.00% | -100.0% |
| Q3 2019 | $13,000 | -27.8% | 2,668 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $18,000 | -10.0% | 2,668 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $20,000 | -9.1% | 2,668 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $22,000 | -35.3% | 2,668 | 0.0% | 0.00% | -50.0% |
| Q3 2018 | $34,000 | +13.3% | 2,668 | 0.0% | 0.00% | +100.0% |
| Q2 2018 | $30,000 | – | 2,668 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 450,000 | $846,000 | 0.90% |
| Skylands Capital, LLC | 2,944,670 | $5,535,980 | 0.84% |
| Sargent Investment Group, LLC | 1,257,048 | $2,363,250 | 0.57% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 197,940 | $372,127 | 0.52% |
| Avenir Corp | 2,717,397 | $5,108,706 | 0.48% |
| Granahan Investment Management | 1,552,393 | $2,918,499 | 0.10% |
| Seelaus Asset Management LLC | 20,450 | $38,446 | 0.04% |
| HighMark Wealth Management LLC | 10,000 | $18,800 | 0.02% |
| Key Client Fiduciary Advisors, LLC | 13,000 | $24,440 | 0.02% |
| Eudaimonia Partners, LLC | 23,500 | $44,180 | 0.01% |